Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines? If so, how often do you check?
Related Questions
How would you treat rapidly growing inflammatory breast cancer, invasive lobular triple negative subtype, after two cycles of neoadjuvant KEYNOTE 522?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
What is your treatment approach in patients with early breast cancer with axillary soft tissue involvement, with or without concurrent lymph node involvement?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
What are your top takeaways from ESMO 2023?
What factors would you consider when deciding between tamoxifen vs OFS/AI in premenopausal women with early stage HR+ breast cancer?
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
What are your top takeaways from SABCS 2023?
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
